Onconetix Stock Set to Reverse Split on Tuesday, September 24th (NASDAQ:ONCO)

Onconetix, Inc. (NASDAQ:ONCO) shares are scheduled to reverse split on Tuesday, September 24th. The 1-40 reverse split was announced on Friday, September 20th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, September 23rd.

Onconetix Price Performance

ONCO stock traded down $0.03 during trading on Friday, reaching $0.08. The company’s stock had a trading volume of 5,121,641 shares, compared to its average volume of 6,247,411. Onconetix has a 1 year low of $0.08 and a 1 year high of $0.62. The company has a current ratio of 0.10, a quick ratio of 0.09 and a debt-to-equity ratio of 0.08. The company’s fifty day moving average is $0.14 and its 200-day moving average is $0.15.

Onconetix (NASDAQ:ONCO) last issued its quarterly earnings results on Thursday, August 29th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $0.71 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 1.37% of Onconetix as of its most recent SEC filing. 23.89% of the stock is currently owned by hedge funds and other institutional investors.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.